



Stockholm, 23 September 2019

PRESS RELEASE

Lipidor has been approved for listing on the Nasdaq First North Growth Market with first day of trading on September 27, 2019

Nasdaq Stockholm AB today approved the application of Lipidor AB ("Lipidor" or "the Company") for admission to trading of Lipidor shares and TO1 series warrants on the Nasdaq First North Growth Market ("Nasdaq First North"). The first day of trading is set for September 27, 2019. In connection with the application, Lipidor has prepared a company description that has been approved by Nasdaq First North, now available on Lipidor's website (www.lipidor.se).

Background

On 16 September, Lipidor announced that its issue of SEK 25.2 million was subscribed for a total of SEK 136 million (corresponding to a subscription rate of approximately 540%). The Company adds approximately 1,150 new shareholders through the share issue and a total of 4,200,000 shares and 2,100 series warrants are issued. The warrants can further provide the Company with a minimum of SEK 18.9 million and a maximum of SEK 25.2 million in November 2020. Full terms and conditions for the TO1 series warrants can be found in the company description available on Lipidor's website (www.lipidor.se).

The short name for the Company's shares on Nasdaq First North is LIPI. The short name for the TO1 series warrants is LIPI TO1.

Through the listing on Nasdaq First North, Lipidor is provided funding for further studies as well as expanding its shareholder base. Lipidor intends, at different occasions, to enter into commercial agreements with pharmaceutical companies and the listing on Nasdaq First North is considered to have a positive impact on the Company's commercial opportunities.

Advisors

Corpora Fondkommission AB is the financial advisor in connection with the Offer and the Company's Certified Adviser. The legal advisor to the Company in connection with the issue was Frederesen Advokatbyrå AB.

Information

The information above was provided by Lipidor AB in accordance with EU Market Abuse Regulations. The information was provided, through the below contact person, for publication on 23 September 2019 at 13:15 CET.

For more information, please contact:

Ola Holmlund, CEO, Lipidor AB
Phone: +46 (0)72 50 70 369
E-mail: ola.holmlund@lipidor.se



Stockholm, 23 September 2019

PRESS RELEASE

Certified Advisor

Corpura Fondkommission AB
Telephone: +46 (0)76 85 32 822
E-mail: ca@corpura.se

About Lipidor

Lipidor is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phase. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.